Roivant Sciences, Inc.
NEWS
Aruvant’s pipeline anchored by RVT-1801, an investigational gene therapy for sickle cell disease and β-thalassemia
As more and more western pharmaceutical companies are pouring money into China, it’s only natural that there is a bit of western “brain drain” as well. A recent NPR report highlighted a number of U.S.-based scientists who have sought career advancement in China.
Roivant Sciences teamed with Cincinnati Children’s Hospital Medical Center to launch Aruvant Sciences. Roivant is the umbrella company run by Vivek Ramaswamy, which has launched a number of companies with “vant” in the names.
Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
JOBS
IN THE PRESS